Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Vinci

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Journal of Hepatology|August 22, 2019
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failureElisabetta Degasperi, Angiola Spinetti, Andrea Lombardi, et al.
Cancer Discovery|November 5, 2021
DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial InhibitionElisa Izquierdo, Diana M Carvalho, Alan Mackay, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 15, 2018
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?Loreta A Kondili, Sarah Robbins, Sarah Blach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2025
The spectrum of IDH- and H3-wildtype high-grade glioma subgroups occurring across teenage and young adult patient populationsRita Pereira, Alan Mackay, Yura Grabovska, et al.
Hepatology (Baltimore, Md.)|July 26, 2017
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohortLoreta A Kondili, Federica Romano, Francesca Romana Rolli, et al.
Journal of Hepatology|November 26, 2018
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis CRoberta D'Ambrosio, Luisa Pasulo, Massimo Puoti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 10, 2019
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life studyRoberta D'Ambrosio, Luisa Pasulo, Alessia Giorgini, et al.
Neuro-Oncology Advances|March 30, 2026
Characterization of patient-derived site-specific <i>in vivo</i> models of pediatric-type diffuse high-grade glioma using magnetic resonance imagingJessica K R Boult, Diana M Carvalho, Ketty Kessler, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric GliomasMaria B Garcia-Fabiani, Santiago Haase, Kaushik Banerjee, et al.
Neuro-Oncology|November 9, 2025
A Systematic Study of Molecular Diagnosis, Treatment and Prognosis in Infant-Type Hemispheric Glioma): An Individual Patient Data Meta-analysis of 164 patientsLara Chavaz, Aditi Bagchi, Sandeep K Dhanda, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Journal of Hepatology|August 22, 2019
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failureElisabetta Degasperi, Angiola Spinetti, Andrea Lombardi, et al.
Cancer Discovery|November 5, 2021
DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial InhibitionElisa Izquierdo, Diana M Carvalho, Alan Mackay, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 15, 2018
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?Loreta A Kondili, Sarah Robbins, Sarah Blach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2025
The spectrum of IDH- and H3-wildtype high-grade glioma subgroups occurring across teenage and young adult patient populationsRita Pereira, Alan Mackay, Yura Grabovska, et al.
Hepatology (Baltimore, Md.)|July 26, 2017
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohortLoreta A Kondili, Federica Romano, Francesca Romana Rolli, et al.
Journal of Hepatology|November 26, 2018
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis CRoberta D'Ambrosio, Luisa Pasulo, Massimo Puoti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 10, 2019
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life studyRoberta D'Ambrosio, Luisa Pasulo, Alessia Giorgini, et al.
Neuro-Oncology Advances|March 30, 2026
Characterization of patient-derived site-specific <i>in vivo</i> models of pediatric-type diffuse high-grade glioma using magnetic resonance imagingJessica K R Boult, Diana M Carvalho, Ketty Kessler, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric GliomasMaria B Garcia-Fabiani, Santiago Haase, Kaushik Banerjee, et al.
Neuro-Oncology|November 9, 2025
A Systematic Study of Molecular Diagnosis, Treatment and Prognosis in Infant-Type Hemispheric Glioma): An Individual Patient Data Meta-analysis of 164 patientsLara Chavaz, Aditi Bagchi, Sandeep K Dhanda, et al.
Pageof 9